CAGR: 8.2%Current Market Size: USD 11 BillionFastest Growing Region: APAC
Largest Market: North AmericaProjection Time: 2023-2030Base Year: 2022
The Global Smart Diabetes Management market is expected to grow from USD 11 billion in 2022 to USD 20.66 billion by 2030, at a CAGR of 8.2% during the Projection period 2023-2030. The growth of this market is mainly driven owing to the increasing cases of diabetes among people from all age groups.
Blood glucose monitoring systems, lancets, test strips/papers, insulin delivery systems, and mobile applications for diabetes care are some examples of frequently used diabetes gadgets. Blood glucose monitoring systems use blood samples taken from fingers to measure glucose levels. Self-monitoring devices and continuous glucose monitoring devices are the two primary categories of glucose monitoring systems. Devices for continuous glucose monitoring take glucose levels using a tiny sensor implanted beneath the skin. This sensor keeps track of fluid glucose levels, often known as interstitial glucose between cells. Lancets are plastic handles with a little needle fastened inside. These are primarily utilized collect blood samples from diabetic patients' fingertips. Three different types of insulin administration systems—insulin pumps, insulin pens, and insulin syringes and needles—can be distinguished. Insulin is delivered to the user by small, automated insulin pumps at predetermined times. Insulin pens are pen-shaped, single-use, or reusable devices with disposable needles. Over the course of the Projection period, it is anticipated that rapid developments in insulin delivery devices, rising investment in the creation of advanced diabetic care devices, and the rapid construction of advanced healthcare infrastructure in emerging nations will all significantly contribute to the growth of the global diabetes devices market.
Sample Request: - Global Smart Diabetes Management Market
Market Dynamics:
Drivers:
By 2030, diabetes is predicted to overtake heart disease as the seventh largest cause of mortality. Stress, sedentary habits, poor diets, and obesity are the main causes of diabetes among people of all ages. Physiological changes brought on by ageing play a sizable role in diabetes risk. For instance, the International Diabetes Federation claims that the prevalence of diabetes rises with age. Therefore, those over 65 are thought to have the highest prevalence. According to diabetes projections for 2021, diabetes prevalence rises with age. For 2045, similar developments are predicted. Adults aged 20 to 24 have the lowest prevalence of diabetes (2.2% in 2021). Diabetes prevalence is predicted to reach 24.0% among persons aged 75 to 79 in 2021 and to rise to 24.7% by 2045. According to these figures, the prevalence of diabetes will significantly rise over the next 25 years in nations with substantial geriatric populations. Therefore, it is anticipated that the need for digital diabetes management solutions will be driven by the growing elderly population and increased exposure to the main risk factors.
Restraints:
Stringent security is needed for Smart Diabetes Management solutions like medical applications, Electronic Health Records (EHRs), and e-prescriptions in order to prevent data breaches and guarantee the safety, privacy, and security of patient data. Since patient healthcare data includes a variety of confidential information, including medical and health-related details, insurance information, social security information, and demographic data, among other things, the growing number of cyber security threats have raised major concerns about patient data safety. An increase in cyberattacks on hospitals and other medical facilities, as well as data security breaches, can result in the loss of vital data and serious penalties, as well as harm the reputation of the hospital or medical facility. This will constrain Smart Diabetes Management technologies unless appropriate remedial and data control mechanisms are implemented.
Opportunities:
Rapid technical advancements and innovations in healthcare-based Diagnostic Centers have affected the digital health sector. The creation of the newest and upgraded healthcare-related apps and Diagnostic Centers, such as payment process integration, video conferencing, co-pay, digital appointment scheduling, etc., is due to an increase in the use of smartphones for daily tasks. These technological advancements are now features of every telehealth product on the market. According to the Commonwealth Fund, the proportion of medical practices that offered the four online features—asking for appointments, requesting prescription refills, accessing test results, and checking visit summaries—was highest in the United States (50%) and Sweden (58%) in 2019.
Challenges:
A smartphone-connected insulin pump, for example, can cost between USD 4,500 and USD 6,500. Additionally, the cost of selling sensor-based continuous glucose monitors ranges from USD 1,000 to USD 1,400, with sensors needing to be changed every few days. Digital blood glucose meters for self-monitoring sell for between $15 and $20. Modern devices are out of reach for a considerable majority of end users, especially those in developing countries with unfavourable reimbursement scenarios due to the high initial cost and frequent use of associated consumables (requiring recurrent purchases). In wealthy nations, most commercial health plans pay the cost of commercially marketed devices. Still, in underdeveloped nations, discrepancies in reimbursement practices frequently lead to non-compliance with treatment. Diabetes patients in China and India must pay the full cost of insulin, integrated CGM systems, blood glucose monitors, and upkeep. Therefore, it is projected that the adoption of digital diabetes management systems will be constrained in the upcoming years due to the high costs and lack of reimbursements in developing nations.
Segmentation Analysis:
The global Smart Diabetes Management market has been segmented based on product, type, end-use, and regions.
By Product
The Product segment is smart glucose meter, smart insulin pens, smart insulin pumps, continuous blood glucose monitoring system, and apps. The continuous blood glucose monitoring system segment led the largest share of the Smart Diabetes Management market with a market share of around 22% in 2022. The segment is expanding because of its sophisticated features, like connectivity with smart gadgets that act as display devices. Additionally, it can be configured to notify patients in a specific way when specific glucose thresholds are achieved. The market has been divided into categories based on the product, including apps, continuous blood glucose monitoring devices, smart insulin pens, smart insulin pumps, and smart glucose meters.
By Type
The type segment includes wearable devices and handheld devices. The wearable devices segment led the Smart Diabetes Management market with a market share of around 53% in 2022. The segment's expansion can be attributed to ongoing technical improvements, the incorporation of remote monitoring technologies into devices, an increase in product introductions, and increased accessibility and patient population awareness. Technology breakthroughs like the emergence of artificial intelligence, the introduction of novel technologies like closed-loop pump systems and smart insulin patches, and the expanding use of self-insulin delivery devices in diabetes treatment are largely to blame for the market's expansion.
By End-Use
The End-Use segment includes hospital, home settings, and diagnostic centers. The home settings segment led the Smart Diabetes Management market with a market share of around 35% in 2022. Future product uptake in home settings will be aided by rising diabetes awareness, user-friendly interfaces of cutting-edge digital devices, ease of use at home, and the convenience of data exchange with specialists via digital platforms. Additionally, the COVID-19 pandemic has boosted the market for digital diabetes management products using linked devices and mobile applications at home.
Global Smart Diabetes Management Market- Sales Analysis.
The sale of synthetic biology Products expanded at a CAGR of 6.6% from 2016 to 2022.
The increasing prevalence of diabetes and companies are spending money on R&D to create improved solutions for the Smart Diabetes Management industry.
The surge in diabetes cases worldwide is being attributed to fast-evolving lifestyles, such as smoking and alcohol intake. Additionally, one of the main causes of diabetes is obesity. With the rising number of obese people and greater patient awareness, the market for diet and weight control apps is showing enormous promise. Diabetes is a medical illness when the body's glucose levels rise due to the pancreas' failure to make insulin. The impact of food and activity on sugar levels, interpreting medical advice, and choosing what to eat are just a few of the daily issues faced by diabetic people. By communicating with the medical staff and exchanging data, patients may take care of their health issues thanks to digital technology's anytime, anywhere nature. As a result, a digital ecosystem of data-driven solutions is developing that can link patients and the people providing their care for improved diabetes control.
The COVID-19 pandemic has had a favourable effect on the market expansion for digital diabetes management devices. Managing blood glucose levels became crucial when patients with serious lung infections were admitted to hospitals. The patient's blood glucose levels significantly changed due to the disease-treating medications. The Centers for Disease Control and Prevention also noted that individuals with COVID-19 diagnoses who also have diabetes were admitted to critical care. Consequently, there was a marked increase in the requirement for diabetes control devices.
Thus, owing to the aforementioned factors, the global smart diabetes management Market is expected to grow at a CAGR of 8.2% during the Projection period from 2023 to 2030.
By Regional Analysis:
The regions analyzed for the Smart Diabetes Management market include North America, Europe, South America, Asia Pacific, the Middle East, and Africa. The North American region dominated the Smart Diabetes Management market and held a 36% share of the market revenue in 2022.
Global Smart Diabetes Management Market- Country Analysis:
Germany's Smart Diabetes Management market size was valued at USD 0.43 billion in 2022 and is expected to reach USD 0.68 billion by 2030, at a CAGR of 6% from 2023 to 2030. The key trends and opportunities in the Smart Diabetes Management market as well as future trends are growing as a result of factors like rising smartphone adoption, improved internet connectivity, improved healthcare IT infrastructure, rising healthcare costs, rising prevalence of chronic diseases, rising demand for remote patient monitoring Diagnostic Centers, and increasing accessibility of virtual care which fuels the market in the region.
China’s Smart Diabetes Management market size was valued at USD 1.58 billion in 2022 and is expected to reach USD 2.83 billion by 2030, at a CAGR of 7.6% from 2023 to 2030. The market is developing as a result of increasing smartphone adoption, rising government spending on healthcare industry upgrades, and rising public awareness of Smart Diabetes Management.
India's Smart Diabetes Management market size was valued at USD 1 billion in 2022 and is expected to reach USD 1.71 billion by 2030, at a CAGR of 7% from 2023 to 2030. The region's market is growing as a result of improvements in IT infrastructure and the emergence of entrepreneurial endeavors, both of which have a substantial impact on the market's growth. The Indian market is expanding as a result of increasing smartphone adoption, rising wearables and activity tracker use, and the rising need for healthcare analytics.
Key Industry Players Analysis:
To increase their market position in the global Smart Diabetes Management business, top companies focus on tactics such as adopting new technology, mergers & acquisitions, Product developments, collaborations, partnerships, joint ventures, etc.
Latest Development:
Report Metrics
Report Attribute |
Details |
Study Period |
2022-2030 |
Base year |
2022 |
CAGR (%) |
8.2% |
Market Size |
11 billion in 2022 |
Projection period |
2023-2030 |
Projection unit |
Value (USD) |
Segments covered |
By Product, By Type, By End-Use, and By Region. |
Report Scope |
Revenue Projection, competitive landscape, company ranking, growth factors, and trends |
Companies covered |
F. Hoffmann-La Roche Ltd., Abbott Laboratories, Medtronic plc, Insulet Corporation, Ascensia Diabetes Care Holdings Ag, Bayer AG, Lifescan, Inc., Dexcom, Inc., Sanofi, and B Braun Melsungen AG. |
By Product |
|
By End-Use |
|
By Type |
|
Regional scope |
|
Scope of the Report
Global Smart Diabetes Management Market by Product:
Global Smart Diabetes Management Market by Type:
Global Smart Diabetes Management Market by End-Use:
Global Smart Diabetes Management Market by Region:
The global market for Smart Diabetes Management was more than USD 11 billion in 2022 and is set to depict a CAGR of over 8.2% through 2023-2030, due to the rising acceptance of remote patient monitoring Diagnostic Centers.
Global Smart Diabetes Management market is growing owing to rise in diseases around the world.
Continuous Blood Glucose Monitoring Systems dominated the Smart Diabetes Management market in Product.
The North America region accounted for the highest Smart Diabetes Management market share.
Political Factors- There is no denying the importance of the political climate for medical equipment. It directly impacts the realization and effectiveness of medical activities and overall economic efficiency as an essential component of institutional quality. In this industry, important variables include the legislative landscape and power distribution. The actions of the government and other state institutions may substantially impact the healthcare sector. Legislation about medical equipment, such as smart diabetes management, is discussed in this section. Global market regulations are based on the US FDA and are similar to those in the People's Republic of China, Europe, and Canada. Classes, I, II, and III are used to categorize medical devices. From Class I to Class III, regulatory oversight is more stringent. The regulatory specifications for a general device type are specified in the device classification regulation.
Economical Factors- Economically, the world currently has modest growth, and little is likely to change in the foreseeable future. Economic activity is anticipated to improve slightly; if at all, the unemployment rate will only slightly decline. While things are improving, there are still short-term threats, including issues with the Eurozone, the USA's inability to overcome fiscal adjustments, and a slowdown in developing nations' economies. Some developed economies implemented risky and unorthodox monetary policies regarding medium-term risks to enhance global financial stability.
Social Factor- The population's demographics, employment rate, level of education, household income, and other factors all influence the social and cultural environment. The ageing population in industrialized economies will fuel the expansion of medical device companies. Over 80% of adults 65 and older have at least one chronic illness. The number of people who are 60 or older will rise sharply. The first wave of baby boomers will start turning 65 in 2012, creating significant potential for medical device businesses with cutting-edge solutions to treat chronic diseases. By 2020, the EU policy is to achieve 40%. The EU's demographic trend works against this goal. The governments of the selected EU nations set the maximum number of approved students.
Technological Factors- Government funding for R&D, the general degree of technology adoption, and new discoveries, for instance, are some technological elements that impact economic growth. The situation in the EU and the market for medical devices will also be discussed in relation to these three sectors. Risk capital investment, private money invested in businesses that create new goods and technologies, is another important component of R&D development. This money is typically invested in these businesses during their startup and expansion phases. These investments are at their highest levels in Bulgaria, Romania, and Greece. The medical technology sector is renowned for its high-calibre R&D and for working closely with customers to produce ever-evolving products.
Environmental Factors- Healthcare facilities should constantly enhance their waste disposal procedures. The goal is to address the population's environmental concerns in particular. As a result, they ought to incorporate such actions into their strategic planning. Despite the business's difficulties, a new survey by GlobalData found that the medical device industry is not doing enough to be more ecologically friendly. 58% of respondents disagreed that the industry was doing enough, while 42% agreed. Medical device businesses and the healthcare sector should still practice environmental responsibility wherever possible, even though the medical device industry is subject to strict regulations, particularly compared to other industries.
Legal Factors- When smart diabetes management is marketed in the EU, it must adhere to the appropriate Directive. The medical device directive covers a wide range of medical devices, including walking aids, implanted devices, and computed tomography scanners. As a result, the level of medical device assessment differs depending on the device's assessed risk. Before their products may be put on the market, businesses must have notified bodies to assess their quality procedures and technical documentation for medium- and high-risk devices. Before issuing a certification, the notified body must confirm that the pertinent standards are met. Manufacturers can then display their products' regulatory conformity by applying the European Conformity (CE) label.
List of Table
List of Figures